Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Qiu Li, Doctor
- Phone Number: 86-23-63612114
- Email: dr.liux0217@gmail.com
Study Locations
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400000
- Children's Hospital of Chongqing Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children older than 5 years who were admitted to the Department of Urology, Children's Hospital Affiliated to Chongqing Medical University and diagnosed with dry OAB.
- The results of our laboratory indicated that the serum vitamin D level was lower than 35ng/mL.
- The child (guardian) has been informed of the nature of the study, understands the provisions in the protocol, is able to guarantee compliance, and signs the informed consent.
Exclusion Criteria:
- Patients with other urinary system malformations or serious diseases (such as hypospadias, cryptorchidism, posterior urethral valvular disease, vesicoureteral reflux, neurogenic bladder, urinary system tumors, urinary calculi, bladder and urethral injuries, etc.);
- complicated with neurological diseases (such as epilepsy, spinal cord injury, spinal cord dysplasia, tethered cord syndrome, multiple sclerosis, autism spectrum disorder, etc.);
- Patients with severe heart disease, abnormal liver and kidney function, lung disease, bone malformation, severe digestive tract disease, and genetic metabolic disease;
- History of gastrointestinal surgery and urinary system surgery;
- Dry stool, long-term constipation;
- are taking anticonvulsant and antiepileptic drugs, hormones, antituberculosis drugs;
- Previous history of hypercalcemia, hyperphosphatemia with renal rickets;
- History of unexplained hematuria and urinary tract infection in the past 1 year;
- Have a history of allergy or allergic reaction to vitamin D preparations;
- Participating in another clinical study at the time of visit or during the follow-up of another clinical study;
- Those who did not want to participate in the study or had poor follow-up compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Standard Behavioral Therapy Combined with Solifenacin Drug Treatment
Solinasine succinate 5mg once daily with a maximum dose of 10mg/day.
Standard Behavioral Therapy
|
The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally
Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later.
Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
|
|
Experimental: Standard behavioral therapy combined with short-term high dose exogenous vitamin D supplementation
Oral vitamin D drops, 2400iu/d, continued for 6 weeks after follow-up.
Standard Behavioral Therapy
|
Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later.
Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
The outpatient physician prescribed vitamin d drops (2400iu daily) for the participants, which were taken orally by the participants
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in daily urination frequency
Time Frame: week 1, week6,week 12
|
To explore whether standard behavioral therapy combined with short-term high dose vitamin D (2400IU daily) is superior to standard behavioral therapy combined with anticholinergic drugs (Solinaxine) in improving the daily frequency of urination in children with dry OAB.
|
week 1, week6,week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the mean urgency score
Time Frame: week 1, week6,week 12
|
To explore whether standard behavioral therapy combined with short-term high dose exogenous vitamin D supplementation (2400IU daily) is superior to standard behavioral therapy combined with anticholinergic drugs (Solinaxine) in improving mean urinal urgency scores in children with dry OAB.
|
week 1, week6,week 12
|
|
Change quality of life score
Time Frame: week 1, week6,week 12
|
Quality of life scores are assessed on a scale of 0 to 3, where 0 indicates no impact on family, social or academic life; A score of 1 represents occasional effects; A score of 2 is a significant impact.
A score of 3 indicates a serious impact on family, social or school life
|
week 1, week6,week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Urinary Bladder, Overactive
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Polycyclic Compounds
- Steroids
- Fused-Ring Compounds
- Heterocyclic Compounds, Bridged-Ring
- Secosteroids
- Tetrahydroisoquinolines
- Isoquinolines
- Quinuclidines
- Solifenacin Succinate
- Vitamin D
Other Study ID Numbers
Other Study ID Numbers
- 202453
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.